Zanamivir

扎那米韦

Report date: 2022/01/14 13:23:58
NMEFirst In Class

Base Information

Drug NameZanamivir
Drug Alias NameZanamivirum扎那米伟Relenza依乐韦GR-121167 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeuraminidase inhibitors
TargetsNeuraminidase
Therapy Area/IndicationsDiabetes Mellitus, Type 2ArthralgiaOrthomyxoviridae Infections +[5] 
Global Approved IndicationsInfluenza, Human
Approved Indications in ChinaInfluenza, Human
Original Approved Country/TerritoryUnited States
Original Approved Date1999/07/26
Country/TerritoryCanadaUnited StatesPoland +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Trading Services LtdGlaxosmithkline PlcUniversity Of Missouri +[5] 
Inactive CompaniesGlaxo Group LtdGlaxo Operations Uk LtdJiangsu Simcere Pharmaceutical Co Ltd +[4] 
Active IndicationsDiabetes Mellitus, Type 2ArthralgiaDengue +[4] 
Inactive IndicationsOrthomyxoviridae Infections

Other Information

ATC CodeJ05AH01
Related LinksWikipediaDrugBankKEGG